Fig. 1

Effects of diet and topiramate treatment on body composition and blood glucose in CD-1 mice. A schematic diagram illustrating the difference in design between arm 1 and 2 of the study (a). Total body weight over the 16 weeks of TPM treatment for arm 1 (b; started with HF diet and thus prior to obesity) and arm 2 (f; started after establishment of obesity). HF consumption led to significant increases in body weight compared to LF diet in both arms. Topiramate treatment had no effect on weight gain. Change in fat mass as a percentage calculated using fat mass measured at the beginning and end of the treatment cycle for arm 1 (c) and arm 2 (g) of the study. Change in lean mass presented as a percentage change from the beginning of the treatment cycle for arm 1 (d) and arm 2 (h) of the study. Topiramate had no effect on lean and fat mass. Nonfasted measurements of blood glucose over the 16 week treatment period for arm 1 (e) and arm 2 (i). In both arms, HF feeding led to a significant increase in nonfasted blood glucose, which was not effected by TPM treatment. Values are expressed as mean ± SD. Significance was determined by a one-way analysis of variance followed by Newman–Keuls post-test for HF vs. LF, LF vs. LF TPM, and HF vs. HF TPM. *p < 0.05; **p < 0.01; ^#p < 0.001